70026-89-0

Basic information

• Product Name: ETHYL 1,2-DIHYDRO-6-METHYL-3-NITRO-2-OXO-4-PYRIDEINCARBOXYLATE
• Synonyms: ETHYL 1,2-DIHYDRO-6-METHYL-3-NITRO-2-OXO-4-PYRIDEINCARBOXYLATE;ethyl 6-methyl-3-nitro-2-oxo-1,2-dihydropyridine-4-carboxylate
• CAS NO: 70026-89-0
• Molecular Formula: C9H10N2O5
• Molecular Weight: 0
• Mol File: 70026-89-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 375.6°C at 760 mmHg
• Flash Point: 181°C
• Appearance: /
• Density: 1.36g/cm³
• Vapor Pressure: 7.68E-06mmHg at 25°C
• Refractive Index: 1.546
• CAS DataBase Reference: ETHYL 1,2-DIHYDRO-6-METHYL-3-NITRO-2-OXO-4-PYRIDEINCARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 1,2-DIHYDRO-6-METHYL-3-NITRO-2-OXO-4-PYRIDEINCARBOXYLATE(70026-89-0)
• EPA Substance Registry System: ETHYL 1,2-DIHYDRO-6-METHYL-3-NITRO-2-OXO-4-PYRIDEINCARBOXYLATE(70026-89-0)

Safety Data

• Hazardous Substances Data: 70026-89-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10N2O5/c1-3-16-9(13)6-4-5(2)10-8(12)7(6)11(14)15/h4H,3H2,1-2H3,(H,10,12)

Upstream product

• 615-79-2 ethyl 2,4-diketopentanoate 
• 14011-21-3 2-nitroacetamide 

Downstream Products

• 221349-77-5 ethyl 2-methoxy-6-methyl-3-nitropyridine 4-carboxylate 

Relevant articles and documents

TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X11 and X22 are independently C or N, provided that zero or one of X11 and X22 is N; Ring A represented by the structure is: or; and Q, R11, R22, R33, R44, R66, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

THROMBIN INHIBITORS

Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure: or a pharmaceutically acceptable salt thereof, whereinA is whereinY 1 and Y 2 are independentlyhydrogen,C 1-4 alkyl,C 1-4 alkoxy,F uH v C(CH 2) 0-1 O--, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1,C 3-7 cycloalkyl,thio C 1-4 alkyl,C 1-4 sulfinylalkyl,C 1-4 sulfonylalkyl, halogencyano, ortrifluoromethyl, andwherein b is 0 or 1.